25 years ago, the FDA approved a pill that would change the way scientists treat cancer … for good. The pill was called Gleevec; it was designed specifically to treat CML, chronic myeloid leukemia, and it was one of the first targeted cancer therapies available. A quarter century after approval, it’s still being prescribed, as are second, third and fourth-generation drugs that followed in its footsteps. What made it so special – and so effective? Pharmaceutical correspondent Sydney Lupkin walks us through the history of the drug, and why it’s continued to change lives for decades.
If you liked this episode, check out our other episodes with Sydney on accelerated drug approvals and the development of GLP-1 pills.
Interested in more stories about medicine and medical treatment? Email us your question at shortwave@npr.org.
Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy

SHARE

COMMENT

VOICE_COMMENT

COMMENT_PAGE

CLAP

PICK

VOTE

AI_SUMMARIZE

New discoveries, everyday mysteries, and the science behind the headlines — in just under 15 minutes. It's science for everyone, using a lot of creativity and a little humor. Join hosts Emily Kwong and Regina Barber for science on a different wavelength.

If you're hooked, try Short Wave Plus. Your subscription supports the show and unlocks a sponsor-free feed. Learn more at plus.npr.org/shortwave

AI_SUMMARIZE_EPISODE

Short Wave

Without this pill, lots of people would be dead

5e75a544418a84a04631b31e/li2xYSzmgi_ukuK-xIEtX-bJFFzx.mp3